2014
DOI: 10.1126/scitranslmed.3008782
|View full text |Cite
|
Sign up to set email alerts
|

PCSK9 is a critical regulator of the innate immune response and septic shock outcome

Abstract: A decrease in the activity of proprotein convertase subtilisin/kexin type 9 (PCSK9) increases the amount of lowdensity lipoprotein (LDL) receptors on liver cells and, therefore, LDL clearance. The clearance of lipids from pathogens is related to endogenous lipid clearance; thus, PCSK9 may also regulate removal of pathogen lipids such as lipopolysaccharide (LPS). Compared to controls, Pcsk9 knockout mice displayed decreases in inflammatory cytokine production and in other physiological responses to LPS. In huma… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

16
384
2
2

Year Published

2015
2015
2020
2020

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 304 publications
(404 citation statements)
references
References 50 publications
16
384
2
2
Order By: Relevance
“…Hepatic steatosis contributes to augmented hepatic ER stress, mitochondrial dysfunction and insulin resistance (24,25). Moreover, it may impair the hepatic clearance of LPS (26). As shown in the current animal study and in other clinical observations (17,27), LPS strongly activates lipolysis in WAT, which could instigate a vicious positive feedback loop between WAT lipolysis, hepatic lipid accumulation and hepatic LPS clearance.…”
Section: Discussionmentioning
confidence: 72%
“…Hepatic steatosis contributes to augmented hepatic ER stress, mitochondrial dysfunction and insulin resistance (24,25). Moreover, it may impair the hepatic clearance of LPS (26). As shown in the current animal study and in other clinical observations (17,27), LPS strongly activates lipolysis in WAT, which could instigate a vicious positive feedback loop between WAT lipolysis, hepatic lipid accumulation and hepatic LPS clearance.…”
Section: Discussionmentioning
confidence: 72%
“…An interesting alternative is to target the organism to reduce inflammation. Proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors lower low density lipoprotein (LDL) levels and may also increase clearance of pathogen lipids, such as LPS, transported in LDL [92]. This novel therapeutic strategy requires further basic and clinical trial investigations.…”
Section: Novel Anti-inflammatory Therapiesmentioning
confidence: 99%
“…PCtargeted therapies are foreseeable in the near future, most imminent among them being the treatment of hypercholesterolemia and cardiovascular with inhibitors of PCSK9 (Wu et al 2015). Anti-PCSK9 therapies may also be applicable to infectious diseases as suggested by the resistance to bacterial septic shock of carriers of hypocholesterolemic mutations in its gene (Walley et al 2014).…”
Section: Importance Of the Pcs In Human Biologymentioning
confidence: 99%